These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

869 related articles for article (PubMed ID: 25492994)

  • 1. Microbiota and the gut-liver axis: bacterial translocation, inflammation and infection in cirrhosis.
    Giannelli V; Di Gregorio V; Iebba V; Giusto M; Schippa S; Merli M; Thalheimer U
    World J Gastroenterol; 2014 Dec; 20(45):16795-810. PubMed ID: 25492994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bacterial translocation in patients with liver cirrhosis: physiology, clinical consequences, and practical implications.
    Ponziani FR; Zocco MA; Cerrito L; Gasbarrini A; Pompili M
    Expert Rev Gastroenterol Hepatol; 2018 Jul; 12(7):641-656. PubMed ID: 29806487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gut microbiota and host metabolism in liver cirrhosis.
    Usami M; Miyoshi M; Yamashita H
    World J Gastroenterol; 2015 Nov; 21(41):11597-608. PubMed ID: 26556989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gut microbiota-related complications in cirrhosis.
    Gómez-Hurtado I; Such J; Sanz Y; Francés R
    World J Gastroenterol; 2014 Nov; 20(42):15624-31. PubMed ID: 25400446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of artesunate supplementation on bacterial translocation and dysbiosis of gut microbiota in rats with liver cirrhosis.
    Chen YX; Lai LN; Zhang HY; Bi YH; Meng L; Li XJ; Tian XX; Wang LM; Fan YM; Zhao ZF; Han DW; Ji C
    World J Gastroenterol; 2016 Mar; 22(10):2949-59. PubMed ID: 26973391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Disorders of gut microflora in the pathogenesis of liver cirrhosis and complications of portal hypertension].
    Anikina EV; Kovtun AV; Iakovenko AV; Gioeva IZ; Iakovenko ÉP; Agafonova NA; Ivanov AN; Volosheĭnikova TV; Grigor'eva IuV
    Eksp Klin Gastroenterol; 2014; (12):20-3. PubMed ID: 26058107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gut-liver axis and probiotics: their role in non-alcoholic fatty liver disease.
    Paolella G; Mandato C; Pierri L; Poeta M; Di Stasi M; Vajro P
    World J Gastroenterol; 2014 Nov; 20(42):15518-31. PubMed ID: 25400436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gut-liver axis, cirrhosis and portal hypertension: the chicken and the egg.
    Arab JP; Martin-Mateos RM; Shah VH
    Hepatol Int; 2018 Feb; 12(Suppl 1):24-33. PubMed ID: 28550391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential mechanisms linking gut microbiota and portal hypertension.
    Baffy G
    Liver Int; 2019 Apr; 39(4):598-609. PubMed ID: 30312513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Intestinal Microbiome and the Liver Transplant Recipient: What We Know and What We Need to Know.
    Doycheva I; Leise MD; Watt KD
    Transplantation; 2016 Jan; 100(1):61-8. PubMed ID: 26647107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gut microbiota and liver diseases.
    Minemura M; Shimizu Y
    World J Gastroenterol; 2015 Feb; 21(6):1691-702. PubMed ID: 25684933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the gut-liver-immune axis to treat cirrhosis.
    Tranah TH; Edwards LA; Schnabl B; Shawcross DL
    Gut; 2021 May; 70(5):982-994. PubMed ID: 33060124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alcoholic liver disease: the gut microbiome and liver cross talk.
    Hartmann P; Seebauer CT; Schnabl B
    Alcohol Clin Exp Res; 2015 May; 39(5):763-75. PubMed ID: 25872593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gut microbiota in alcoholic liver disease: pathogenetic role and therapeutic perspectives.
    Malaguarnera G; Giordano M; Nunnari G; Bertino G; Malaguarnera M
    World J Gastroenterol; 2014 Nov; 20(44):16639-48. PubMed ID: 25469033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is treating the gut microbiome the key to achieving better outcomes in cirrhosis?
    Hatton G; Shawcross DL
    Expert Rev Gastroenterol Hepatol; 2019 Jan; 13(1):1-2. PubMed ID: 30791837
    [No Abstract]   [Full Text] [Related]  

  • 16. Effect of rifaximin on gut microbiota composition in advanced liver disease and its complications.
    Ponziani FR; Gerardi V; Pecere S; D'Aversa F; Lopetuso L; Zocco MA; Pompili M; Gasbarrini A
    World J Gastroenterol; 2015 Nov; 21(43):12322-33. PubMed ID: 26604640
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gut-liver axis signaling in portal hypertension.
    Simbrunner B; Mandorfer M; Trauner M; Reiberger T
    World J Gastroenterol; 2019 Oct; 25(39):5897-5917. PubMed ID: 31660028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical impact of microbiome in patients with decompensated cirrhosis.
    Oikonomou T; Papatheodoridis GV; Samarkos M; Goulis I; Cholongitas E
    World J Gastroenterol; 2018 Sep; 24(34):3813-3820. PubMed ID: 30228776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Salivary microbiota reflects changes in gut microbiota in cirrhosis with hepatic encephalopathy.
    Bajaj JS; Betrapally NS; Hylemon PB; Heuman DM; Daita K; White MB; Unser A; Thacker LR; Sanyal AJ; Kang DJ; Sikaroodi M; Gillevet PM
    Hepatology; 2015 Oct; 62(4):1260-71. PubMed ID: 25820757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Review article: the gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease.
    Woodhouse CA; Patel VC; Singanayagam A; Shawcross DL
    Aliment Pharmacol Ther; 2018 Jan; 47(2):192-202. PubMed ID: 29083037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.